[
  {
    "ts": null,
    "headline": "GeneDx Partners With Komodo Health to Advance Rare Disease Research",
    "summary": "WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.",
    "url": "https://finnhub.io/api/news?id=040c4e88092c977331511d1548d06934a4aaa8f30cded4880ea79cbf6279dcb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768229760,
      "headline": "GeneDx Partners With Komodo Health to Advance Rare Disease Research",
      "id": 138076573,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.",
      "url": "https://finnhub.io/api/news?id=040c4e88092c977331511d1548d06934a4aaa8f30cded4880ea79cbf6279dcb4"
    }
  },
  {
    "ts": null,
    "headline": "Illumina's New Connected Multiomics Platform Set to Boost Its Stock",
    "summary": "ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.",
    "url": "https://finnhub.io/api/news?id=aa20238bffaa438523e4915688649873b19b2d640d93a783e7425a7e349a66e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768223340,
      "headline": "Illumina's New Connected Multiomics Platform Set to Boost Its Stock",
      "id": 138072401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.",
      "url": "https://finnhub.io/api/news?id=aa20238bffaa438523e4915688649873b19b2d640d93a783e7425a7e349a66e0"
    }
  },
  {
    "ts": null,
    "headline": "Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones",
    "summary": "Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a corporate update and outlined upcoming development milestones for NXT-41x, its next-generation antibiotic-eluting biomatrix program in plastic and reconstructive surgery. NXT-41x is El",
    "url": "https://finnhub.io/api/news?id=34ac79e55bfd0a75a316dcd5c91abb7d037896b41468ae94ad9b93d96eb32bf3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768222800,
      "headline": "Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones",
      "id": 138071503,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a corporate update and outlined upcoming development milestones for NXT-41x, its next-generation antibiotic-eluting biomatrix program in plastic and reconstructive surgery. NXT-41x is El",
      "url": "https://finnhub.io/api/news?id=34ac79e55bfd0a75a316dcd5c91abb7d037896b41468ae94ad9b93d96eb32bf3"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation",
    "summary": "Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on the development and commercialization of innovative solutions to treat bladder dysfunction. The company's eCoin® System is an implantable tibial nerve stimulation (ITNS) device for the treatment of urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB).",
    "url": "https://finnhub.io/api/news?id=0f415d40b19ab33785f66e17b5c374a70e3b07e89c2d1dd4c09cc8fd13cbf4a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768219200,
      "headline": "Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation",
      "id": 138071504,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on the development and commercialization of innovative solutions to treat bladder dysfunction. The company's eCoin® System is an implantable tibial nerve stimulation (ITNS) device for the treatment of urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB).",
      "url": "https://finnhub.io/api/news?id=0f415d40b19ab33785f66e17b5c374a70e3b07e89c2d1dd4c09cc8fd13cbf4a3"
    }
  }
]